Men currently have few options for reproductive control, including condoms and vasectomy.
While condoms are widely available and useful in preventing disease when used correctly, they have an 18 per cent yearly pregnancy rate in typical use.
Vasectomy is effective, but must generally be considered permanent. There are no long-acting, reversible contraceptives currently available for men.
The new study in rabbits has confirmed that Vasalgel has the potential to fill the gap in male contraception availability.
"Results from our study in rabbits were even better than expected. Vasalgel produces a very rapid contraceptive effect which lasted throughout the study due to its unique hydrogel properties," said Dr Donald Waller, Professor of Pharmacology and Toxicology at the University of Illinois at Chicago.
"These features are important considerations for a contraceptive product to be used in humans," said Waller, lead author of the research published in the journal Basic and Clinical Andrology.
After the gel was injected into the vas deferens of 12 rabbits, semen analysis showed that 11 rabbits were azoospermic in all samples, having no quantifiable sperm in their semen at all.
One rabbit had a few samples with very small numbers of sperm before also becoming azoospermic. Both test articles were equally effective.
The study also confirmed that the contraceptive effect was durable over the 12 month study period. The response of the vasa deferentia tissue was minimal with characteristics of a normal foreign body response.
Hydrogels allow transit of many water-soluble molecules but not larger structures such as spermatozoa.
The ability to remove the gel to return the flow of sperm - or reverse the contraceptive effect - was successfully accomplished in the rabbit model, researchers said.
Seven rabbits had the test article flushed from their vas deferens, and semen samples showed a rapid return of sperm flow, they said.
The success of the studies has paved the way for the first clinical trial in men, scheduled to launch late this year, researchers said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
